Topotecan or other agents as second-line therapy for relapsed small-cell lung cancer: A meta-analysis of randomized studies

Small cell lung cancer (SCLC) is exceptionally responsive to chemotherapy and radiotherapy. In relapsed patients, particularly in resistant/refractory cases, the progression of disease occurs rapidly with second-line agents. Topotecan (TOPO), a camptothecin analog, is the only agent able to increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fausto, Ghidini, Antonio, Luciani, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408676/
https://www.ncbi.nlm.nih.gov/pubmed/34476102
http://dx.doi.org/10.3892/mco.2021.2383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408676/
https://www.ncbi.nlm.nih.gov/pubmed/34476102
http://dx.doi.org/10.3892/mco.2021.2383

Ejemplares similares